jm3c02384_si_002.csv (5.92 kB)
Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase Activator
dataset
posted on 2024-03-26, 16:37 authored by Christopher G. Thomson, Thomas D. Aicher, Weiwei Cheng, Hongwen Du, Crissy Dudgeon, An-Hu Li, Baozhong Li, Eric Lightcap, Diheng Luo, Mark Mulvihill, Pengwei Pan, Benjamin F. Rahemtulla, Alan C. Rigby, Bradley Sherborne, Sanjeev Sood, David Surguladze, Eric P. A. Talbot, Feven Tameire, Simon Taylor, Yi Wang, Paulina Wojnarowicz, Fenfen Xiao, Savithri RamurthyA series of activators of GCN2 (general control nonderepressible
2) kinase have been developed, leading to HC-7366, which has entered
the clinic as an antitumor therapy. Optimization resulted in improved
permeability compared to that of the original indazole hinge binding
scaffold, while maintaining potency at GCN2 and selectivity over PERK
(protein kinase RNA-like endoplasmic reticulum kinase). The improved
ADME properties of this series led to robust in vivo compound exposure in both rats and mice, allowing HC-7366 to be
dosed in xenograft models, demonstrating that activation of the GCN2
pathway by this compound leads to tumor growth inhibition.
